Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus

Clinical Therapeutics

Volumn 29, Issue SUPPL. B, 2007, Pages

  Zanchetti, Alberto ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

classification; diabetes mellitus; European guidelines; hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFECT; EUROPE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; SALT INTAKE; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 36048933968     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.008     Document Type: Article

References (22)

1. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European SocieW of Cardiology guidelines for the management of arterial hypertension. [published corrections appear in J H ypertens. 2003;21: 2203-2204 and J H ypertens. 2004;22:435]. J H ypertens 21 (2003) 1011-1053
2. Evans J., and Rose G. Hypertension. Br Med Bull 27 (1971) 37-42
3. Chobanian A., Bakris G., Black H., et al., for the National Heart, Lung, and Blood InstituteJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of-the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of- High Blood Pressure: The JNC 7 report [published correction appears in JAMA]. 2003;290:197. JAMA 289 (2003) 2560-2572
4. Cifkova R., Erdine S., Fagard R., et al., for the ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21 (2003) 1779-1786
5. Hansson L., Zanchetti A., Carruthers S., et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. [published correction appears in BMJ. 1999;318: 29]. BMJ 317 (1998) 703-713
7. Adler A., Stratton I., Nell H., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 321 (2000) 412-419
8. Estacio R., Jeffers B., Gifford N., and Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 SuppI 2 (2000) B54-B64
9. Schrier R., Estacio R., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
10. PROGRESS Collaborative Study. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack. Lancet 358 (2001) 1033-1041
11. Zanchetti A., Hansson L., Clemente D., et al., for the HOT Study Group. Benefits and risk of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: Does a J-shaped curve exist in smokers?. J H ypertens 21 (2003) 797-804
12. Turnbull F., Neal B., Algert C., et al., for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arck Intern Med 165 (2005) 1410-1419
13. UK Prospective Diabetes Study Group. Efficacy ofatenolol and captopril in reducing risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
14. Brown M., Palmer C., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). [published correction appears in Lancet. 2005; 356:514]. Lancet 356 (2000) 366-372
15. Estacio R., Jeffers B., Hiatt W., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998) 645-652
16. Lewis E., Hunsicker L., Clarke W., et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
17. Lindholm L., Ibsen H., Dahlof B., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 1004-1010
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 288 (2002) 2981-2997
19. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Neffologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
20. Parving H., Lehnert H., Brochner-Mortensen J., et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
21. Brenner B., Cooper M., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of Iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
22. Ruggenenti P., Fassi A., Ilieva A., et al., for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N EnglJ Med 351 (2004) 1941-1951